Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	TRACON Pharmaceuticals	Genocea Biosciences	Aziyo Biologics	Ayala Pharmaceuticals	Brainstorm Cell Therapeutics
Symbol	NASDAQ:TCON	NASDAQ:GNCA	NASDAQ:AZYO	NASDAQ:AYLA	NASDAQ:BCLI
Price Information
Current Price	$6.30	$2.42	$11.03	$10.16	$3.12
52 Week Range	Buy	Buy	Buy	Buy	Buy
MarketRank™
Overall Score	1.7	1.6	1.4	1.3	1.3
Analysis Score	3.5	3.5	3.5	3.4	3.5
Community Score	2.8	2.8	2.9	2.7	3.0
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	1.7	0.8	0.0	0.0	0.0
Earnings & Valuation Score	0.6	0.6	0.6	0.6	0.0
Analyst Ratings
Consensus Recommendation	Buy	Buy	Buy	Buy	Buy
Consensus Price Target	$16.67	$7.25	$20.00	$24.20	$12.00
% Upside from Price Target	164.55% upside	199.59% upside	81.32% upside	138.19% upside	284.62% upside
Trade Information
Market Cap	$103.72 million	$131.12 million	$115.15 million	$134.53 million	$115.49 million
Beta	2.02	2.33	N/A	N/A	0.37
Average Volume	400,207	513,693	19,013	30,864	1,002,256
Sales & Book Value
Annual Revenue	$3 million	N/A	N/A	$2.33 million	N/A
Price / Sales	32.51	N/A	N/A	57.74	N/A
Cashflow	N/A	N/A	N/A	N/A	N/A
Price / Cash	N/A	N/A	N/A	N/A	N/A
Book Value	$0.67 per share	$0.89 per share	N/A	N/A	($0.54) per share
Price / Book	9.40	N/A	N/A	∞	N/A
Profitability
Net Income	$-22,670,000.00	$-38,950,000.00	N/A	$-17,790,000.00	$-23,250,000.00
EPS	($7.47)	($2.09)	N/A	N/A	($1.06)
Trailing P/E Ratio	N/A	N/A	0.00	0.00	N/A
Forward P/E Ratio	N/A	N/A	N/A	N/A	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	N/A	N/A	N/A	-850.81%	N/A
Return on Equity (ROE)	-273.66%	-237.31%	N/A	-625.24%	-339.86%
Return on Assets (ROA)	-84.56%	-62.30%	N/A	-70.31%	-144.74%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	0.13%	N/A	N/A	N/A	N/A
Current Ratio	2.76%	3.79%	N/A	8.63%	4.72%
Quick Ratio	2.76%	3.79%	N/A	8.63%	4.72%
Ownership Information
Institutional Ownership Percentage	42.03%	53.78%	N/A	12.81%	21.58%
Insider Ownership Percentage	23.30%	2.08%	N/A	N/A	22.10%
Miscellaneous
Employees	18	72	155	34	40
Shares Outstanding	15.48 million	53.52 million	10.23 million	13.24 million	36.32 million
Next Earnings Date	N/A	7/22/2021 (Estimated)	8/3/2021 (Estimated)	6/28/2021 (Estimated)	8/4/2021 (Estimated)
Optionable	Not Optionable	Optionable	Not Optionable	Not Optionable	Optionable

Source	Headline
	Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Sees Significant Drop in Short Interest americanbankingnews.com - May 4 at 7:40 AM
	Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Expected to Announce Earnings of -$0.24 Per Share americanbankingnews.com - April 30 at 6:22 PM
	Equities Analysts Set Expectations for Brainstorm Cell Therapeutics Inc.'s Q2 2021 Earnings (NASDAQ:BCLI) americanbankingnews.com - April 30 at 7:25 AM
	Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Is Worth Evaluating At $3.63 marketingsentinel.com - April 29 at 9:26 AM
	BCLI: Continuing to Receive Feedback on Next Steps for NurOwn®… finance.yahoo.com - April 28 at 7:12 PM
	Brainstorm Cell Therapeutics (NASDAQ:BCLI) Issues Earnings Results americanbankingnews.com - April 27 at 7:18 AM
	BrainStorm Announces First Quarter 2021 Financial Results and Provides a Corporate Update finance.yahoo.com - April 26 at 8:56 AM
	Brainstorm Cell Therapeutics (BCLI) Set to Announce Earnings on Monday americanbankingnews.com - April 20 at 9:30 AM
	What Type Of Shareholders Own The Most Number of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Shares? nasdaq.com - April 9 at 1:10 PM
	Do Institutions Own Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Shares? finance.yahoo.com - April 7 at 8:17 AM
	BCLI: Positive Proof-of-Concept Data for NurOwn in Progressive Multiple Sclerosis… finance.yahoo.com - March 30 at 1:36 PM
	Brainstorm Cell Therapeutics Inc. [BCLI] moved up 3.06: Why It’s Important dbtnews.com - March 25 at 11:30 PM
	Maxim Group Gives a Buy Rating to Brainstorm Cell Therapeutics (BCLI) smarteranalyst.com - March 25 at 6:30 PM
	BrainStorm Announces Positive Data On Cell Therapy NurOwn As Treatment For Progressive MS; Stock Up nasdaq.com - March 24 at 12:14 PM
	Why Is It Moving? Looking Into Why Brainstorm Cell's Stock is Trading Higher Today msn.com - March 24 at 12:14 PM
	BrainStorm Announces Positive Topline Data in Phase 2 Study Evaluating NurOwn® as a Treatment for Progressive MS finance.yahoo.com - March 24 at 7:14 AM
	BCLI: Awaiting BrainStorm’s Decision on NurOwn® BLA Filing… finance.yahoo.com - March 4 at 4:49 PM
	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Brainstorm Cell Therapeutics Inc. - BCLI prnewswire.com - February 24 at 8:24 PM
	BrainStorm to Present at SVB Leerink 10th Global Healthcare Conference finance.yahoo.com - February 23 at 8:19 AM
	Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Brainstorm Cell Therapeutics Inc. (BCLI) Investigation finance.yahoo.com - February 22 at 7:56 PM
	FDA Concludes BrainStorm's ALS Cell Therapy Lacks Substantial Data For Submission; Shares Drop finance.yahoo.com - February 22 at 2:55 PM
	BrainStorm Announces High-Level FDA Feedback on NurOwn® ALS Clinical Development Program finance.yahoo.com - February 22 at 9:54 AM
	We Think Brainstorm Cell Therapeutics (NASDAQ:BCLI) Needs To Drive Business Growth Carefully finance.yahoo.com - February 6 at 8:45 AM
	BCLI: Waiting for Guidance from FDA on Potential Path Forward for NurOwn® in ALS… finance.yahoo.com - February 5 at 1:03 PM
	Why BrainStorm Cell Therapeutics Blasted 27.7% Higher Today finance.yahoo.com - February 4 at 7:57 PM

Date	Company	Brokerage	Action
4/22/2021	TRACON Pharmaceuticals	BTIG Research	Upgrade
4/1/2021	TRACON Pharmaceuticals	Jonestrading	Initiated Coverage
2/10/2021	TRACON Pharmaceuticals	Maxim Group	Initiated Coverage
12/4/2020	TRACON Pharmaceuticals	HC Wainwright	Boost Price Target
3/1/2019	TRACON Pharmaceuticals	Needham & Company LLC	Reiterated Rating
5/3/2021	Genocea Biosciences	Robert W. Baird	Reiterated Rating
4/13/2021	Genocea Biosciences	SVB Leerink	Boost Price Target
7/8/2019	Genocea Biosciences	Stifel Nicolaus	Initiated Coverage
11/2/2020	Aziyo Biologics	Truist	Initiated Coverage
11/2/2020	Aziyo Biologics	Piper Sandler	Initiated Coverage
11/2/2020	Aziyo Biologics	Cowen	Initiated Coverage
11/2/2020	Aziyo Biologics	Cantor Fitzgerald	Initiated Coverage
1/25/2021	Ayala Pharmaceuticals	Noble Financial	Reiterated Rating
12/7/2020	Ayala Pharmaceuticals	Roth Capital	Initiated Coverage
8/13/2020	Ayala Pharmaceuticals	Raymond James	Reiterated Rating
8/13/2020	Ayala Pharmaceuticals	Oppenheimer	Reiterated Rating
6/2/2020	Ayala Pharmaceuticals	Jefferies Financial Group	Initiated Coverage
6/2/2020	Ayala Pharmaceuticals	Citigroup	Initiated Coverage
12/18/2018	Brainstorm Cell Therapeutics	Dawson James	Reiterated Rating

(Data available from 5/6/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources